Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:47:07.299Z.
Calculation as of: 2026-10-06T19:47:07.299Z.
Quote observation: 2026-10-06T19:45:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
PE RATIO
N/A
Market Cap
$258.34M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$260.59M
PE Ratio
N/A
TTM Avg
16.07
3Y Avg
13.93
5Y Avg
35.67
Market Cap
$261.58M
PE Ratio
N/A
TTM Avg
15.73
3Y Avg
15.73
5Y Avg
15.86
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $259.30M | N/A | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $258.91M | N/A | 4.20 | 4.20 | 4.20 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.34M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.98M | N/A | 14.47 | 14.47 | 17.60 |
| OraSure Technologies, Inc. (OSUR)vs › | $260.59M | N/A | 16.07 | 13.93 | 35.67 |
| Palisade Bio, Inc. (PALI)vs › | $261.10M | N/A | 4.44 | 4.44 | 4.44 |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.15M | N/A | 83.73 | 30.92 | 28.56 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.58M | N/A | 15.73 | 15.73 | 15.86 |
| Scribe Therapeutics Inc. (SCTX)vs › | $262.47M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
